Company / FCF Margin
Cue Biopharma, Inc. FCF Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-79.6%
FY2025
5-year range
-3371.7% / -79.6%
FY2021-FY2025
Trend
+79.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has increased for 3 consecutive years, from -3371.7% in FY2022 to -79.6% in FY2025.
Based on SEC 10-K filings.
-79.6% in FY2025 with a 5-year CAGR of +812.3%.
Improved from -727.9% to -79.6% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +3292.1pp
- 5-Year Change
- +812.3pp
- 10-Year Change
- -
Key checks
Key Insights
- Cue Biopharma, Inc.'s fcf margin has grown for 3 consecutive years.
- In FY2025, fcf margin increased 79.7% year-over-year.
- Lowest fcf margin in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -79.6% | +79.7% |
| FY2024 | -391.9% | +46.2% |
| FY2023 | -727.9% | +78.4% |
| FY2022 | -3371.7% | -1167.3% |
| FY2021 | -266.0% | +70.2% |
| FY2020 | -891.9% | +63.9% |
| FY2019 | -2473.8% | -114.6% |
| FY2018 | -1152.8% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026